Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-10-24

Clinical Trial Update: Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the cognitive effects of eslicarbazepine acetate in children with partial-onset seizures; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • eslicarbazepine acetate (eslicarbazepine acetate)

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Partial Epilepsy | Phase 2 | Status: COMPLETED | Results posted: 2014-10-24